Logo Logo Logo Logo Logo
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Medical and Scientific Advisors
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Medical and Scientific Advisors
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers

20 February 2019: Calypso Biotech BV secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases.

Posted at h in Press release

Click to see full press release...

Read More

19 February 2019: AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

Posted at h in Press release

Click to see full press release...

Read More

31 March 2017: Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Posted at h in Press release
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
Read More
  • 1
  • 2

© Calypso Biotech 2024 – Legal disclaimer